Fifth Lane Capital, LP Cerevel Therapeutics Holdings, Inc. Transaction History
Fifth Lane Capital, LP
- $37.3 Million
- Q3 2024
A detailed history of Fifth Lane Capital, LP transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Fifth Lane Capital, LP holds 7,500 shares of CERE stock, worth $0. This represents 0.45% of its overall portfolio holdings.
Number of Shares
7,500Holding current value
$0% of portfolio
0.45%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding CERE
# of Institutions
12Shares Held
5.04MCall Options Held
3.3KPut Options Held
0-
Black Rock Inc. New York, NY3.56MShares$00.0% of portfolio
-
Segantii Capital Management LTD1.14MShares$05.99% of portfolio
-
Tekla Capital Management LLC176KShares$00.22% of portfolio
-
Credit Suisse Ag Zurich, V8112KShares$00.0% of portfolio
-
Virtu Financial LLC New York, NY25.1KShares$00.07% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...